vtv
therapeutics
presents
baseline
characteristics
enrolled
subjects
elevage
study
suggesting
comparability
diabetes
subgroup
phase
steadfast
study
high
point
globe
newswire
vtv
therapeutics
nasdaq
vtvt
today
reported
baseline
characteristics
enrolled
subjects
ongoing
elevage
clinical
study
azeliragon
potential
treatment
mild
alzheimer
disease
ad
people
type
diabetes
data
demonstrate
patients
enrolled
elevage
similar
baseline
characteristics
steadfast
type
diabetes
subgroup
company
reported
october
data
subgroup
demonstrated
nominally
significant
differences
favoring
azeliragon
compared
placebo
instrument
used
evaluate
cognition
goal
elevage
study
confirm
results
retrospective
analyses
phase
study
prior
initiating
phase
study
elevage
data
presented
today
clinical
trials
alzheimer
disease
ctad
conference
digital
event
held
virtually
november
completed
enrollment
part
elevage
pleased
baseline
characteristics
consistent
steadfast
subgroup
saw
benefit
azeliragon
compared
placebo
said
steve
holcombe
president
ceo
vtv
therapeutics
elevage
study
azeliragon
patient
population
designed
sequential
phase
trials
operationally
conducted
one
protocol
phase
data
positive
design
would
allow
us
move
quickly
phase
trial
potential
support
product
approval
approximately
patients
ad
associated
increased
advanced
glycation
endproducts
increased
expression
receptor
advanced
glycation
endproducts
target
azeliragon
believe
azeliragon
could
potentially
important
advance
addressing
dementia
baseline
characteristic
data
presented
today
demonstrate
elevage
patient
population
similar
steadfast
subgroup
respect
age
height
weight
index
apoe
status
background
ad
medication
scores
multiple
cognitive
assessments
including
state
exam
mmse
cdr
global
cdr
sum
boxes
company
expects
report
topline
safety
efficacy
data
part
elevage
study
december
earlier
previously
anticipated
details
ctad
digital
presentation
oral
presentation
title
azeliragon
elevage
study
study
update
preliminary
data
baseline
characteristics
participants
mild
alzheimer
disease
type
diabetes
randomized
part
presentation
number
category
demand
late
breaking
communications
date
time
wednesday
november
available
us
est
elevage
study
elevage
study
randomized
clinical
trial
evaluating
azeliragon
individuals
ages
probable
disease
type
diabetes
objective
elevage
study
replicate
randomized
placebo
controlled
study
results
observed
post
hoc
analysis
phase
ste
ad
fast
trial
subgroup
patients
mild
alzheimer
disease
type
diabetes
treated
azeliragon
demonstrated
nominally
statistically
significant
improvements
cognition
scale
points
month
compared
subgroup
patients
treated
placebo
azeliragon
associated
improvement
nominally
significant
early
month
scale
points
p
vtv
therapeutics
vtv
therapeutics
biopharmaceutical
company
focused
developing
oral
small
molecule
drug
candidates
vtv
pipeline
clinical
drug
candidates
led
programs
treatment
type
diabetes
alzheimer
disease
inflammatory
disorders
vtv
development
partners
pursuing
additional
indications
type
diabetes
chronic
obstructive
pulmonary
disease
copd
genetic
mitochondrial
diseases
information
please
visit
follow
us
twitter
vtvtherapeutics
statements
release
contains
statements
involve
risks
uncertainties
statements
identified
use
terminology
including
terms
anticipate
believe
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
case
negative
various
comparable
terminology
statements
statements
historical
facts
contained
release
including
statements
regarding
timing
clinical
trials
strategy
future
operations
future
financial
position
future
revenue
projected
costs
prospects
plans
objectives
management
expected
market
growth
statements
statements
involve
known
unknown
risks
uncertainties
important
factors
may
cause
actual
results
performance
achievements
materially
different
future
results
performance
achievements
expressed
implied
statements
important
factors
could
cause
results
vary
expectations
include
described
heading
risk
factors
annual
report
form
filings
sec
statements
reflect
views
respect
future
events
date
release
based
assumptions
subject
risks
uncertainties
given
uncertainties
place
undue
reliance
statements
statements
represent
estimates
assumptions
date
release
except
required
law
undertake
obligation
update
review
publicly
statements
whether
result
new
information
future
events
otherwise
date
release
anticipate
subsequent
events
developments
cause
views
change
statements
reflect
potential
impact
future
acquisitions
merger
dispositions
joint
ventures
investments
may
undertake
qualify
statements
cautionary
statements
contacts
investors
corey
davis
lifesci
advisors
cdavis
media
glenn
silver
lazar
finn
partners
gsilver
